United Therapeutics Corporation (UTHR) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

Total Assets Chart for United Therapeutics Corporation

United Therapeutics Corporation (UTHR) total assets for FY2025 were USD 7.9B, a 7.0% change from FY2024. United Therapeutics Corporation's total assets grew from USD 18.7M in 1998 to USD 7.9B in 2025 (42039.0% over 27 years). Total assets compound annual growth rate: 5-year CAGR of 11.3%, 10-year CAGR of 13.7%, 20-year CAGR of 17.9%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$23.23B
Implied Share Price
$541.62
Enterprise Value
$18.22B
Revenue (TTM)
$3.15B
EBITDA
$1.50B
Profit Margin
41.56%
Trailing P/E
19.40
Forward P/E
16.42
Price/Book (MRQ)
3.33
Price/Sales (TTM)
7.36
EV/EBITDA
10.87
EV/Revenue
5.78
Dividend Yield
—
Book Value
$149.97
Free Cash Flow (FY2025)
$1.04B
Free Cash Flow Yield
4.48%

Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.